Reports


Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Research Report 2020-2026 (Includes Business Impact of COVID-19)

  • TBI509233
  • October 21, 2020
  • Global
  • 139 pages
  • TSCIR
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

Nosocomial or hospital-acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug-resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug-resistant, these organisms are immune to conventional antibiotics hence difficult to treat.

Pneumonia is one of the prominent infections caused by hospital premises. Cases of hospital-acquired pneumonia are common in immunocompromised patients, post-surgical infections, enteral feeding, elderly and infant patients. As hospital-acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator-associated pneumonia. Major causative pathogens include methicillin-resistant S. aureus (MRSA), multi drug-resistant (MDR) P. aeruginosa, Klebsiella, and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.

In 2020, the market size of Pipeline Analysis of Hospital Acquired Pneumonia Drugs is xx million US$ and it will reach xx million US$ in 2026, growing at a CAGR of xx% from 2021; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2020 has been considered as the base year and 2021 to 2026 as the forecast period to estimate the market size for Pipeline Analysis of Hospital Acquired Pneumonia Drugs. This report studies the global market size of Pipeline Analysis of Hospital Acquired Pneumonia Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

This study presents the Pipeline Analysis of Hospital Acquired Pneumonia Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019

Market Segmentation: Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

Segmentation by Product Type: Breakdown of data from year 2015 to 2020 and forecast until 2026:
  • Tedizolid Phosphate
  • Ceftolozane/Tazobactam
  • Ceftazidime/Avibactum
  • Amikacin Inhale
  • Plazomicin
  • Synflorix Vaccine
Segmentation by Application: Breakdown of data from year 2015 to 2020 and forecast until 2026:
  • Bacterial Pneumonia
  • Viral Pneumonia
Top Companies & Key Players: Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market The report offers a detailed analysis of several leading Pipeline Analysis of Hospital Acquired Pneumonia Drugs manufacturers including:
  • Achaogen
  • Aridis Pharmaceuticals
  • AstraZeneca
  • Cubist Pharmaceuticals
  • Meiji Seika Pharma
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • Valneva
In October 2020, Nabriva Therapeutics Ireland DAC received marketing authorization valid throughout the European Union for Xenleta which is an antibiotic used in adults to treat community-acquired pneumonia (a lung infection caught outside of the hospital) when other antibiotic medicines are not suitable or do not work. Xenleta was as effective as moxifloxacin at treating community-acquired pneumonia. Its side effects were considered manageable. The active substance in Xenleta, lefamulin, belongs to a group of medicines called pleuromutilins. Lefamulin interferes with bacterial RNA (genetic material), blocking the production of bacterial proteins. This prevents the bacteria from multiplying and they eventually die. The cost for Xenleta intravenous solution (150 mg/15 mL) is around US $650 for a supply of 90 milliliters and 600mg oral table will cost approximately US$4300 in the US. Key Insights Covered: Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry. Research Methodology: Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report. Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others. Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.

Table of Contents
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Tedizolid Phosphate
1.3.3 Ceftolozane/Tazobactam
1.3.4 Ceftazidime/Avibactum
1.3.5 Amikacin Inhale
1.3.6 Plazomicin
1.3.7 Synflorix Vaccine
1.4 
Market Segment by Application

1.4.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Share by Application (2019-2025)
1.4.2 Bacterial Pneumonia
1.4.3 Viral Pneumonia
1.5 Study Objectives
1.6 Years Considered2 Global Growth Trends
2.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Size

|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form